Eledon's Drug Fails Kidney Transplant Trial, Stock Plummets

Eledon Pharmaceuticals stock plummets as tegoprubart fails to meet effectiveness goals in kidney transplant rejection study. Despite disappointing results, the drug shows promising safety profile and maintains strong kidney function. Company plans to proceed with development after regulatory discussions, with cash reserves expected to fund operations until late 2026.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.